Navigation Links
ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
Date:8/7/2008

nd are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007.

ISTA Pharmaceuticals, Inc.

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended S
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased ... office in Charlottetown , PEI.  Bioenterprise ... Edward Island ADAPT Council for the commercialization of agricultural ... to working with PEI ADAPT.  They have been at ... than a decade," explains Dave Smardon , President ...
(Date:4/16/2015)... April 16, 2015  AnaptysBio, Inc., a leader ... antibodies, today announced the advancement of its ... IND-enabling studies. The Company,s anti-IL-36R therapeutic antibody, ... generalized pustular psoriasis (GPP), an orphan systemic ... is wholly owned within AnaptysBio,s proprietary antibody ...
(Date:4/16/2015)... April 16, 2015  EMD Serono today announced ... Germany , appointed Alise ... of Global Clinical Development.  Dr. Reicin brings extensive ... in Oncology and Immunology. She is an accomplished ... as a Vice President in various capacities across ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... Cincinnati has long been known for its world-record-breaking ... Cincinnati have discovered new uses by spinning carbon ... properties. , Breakthroughs Without Broken Threads ... proven to grow carbon nanotubes of world-record breaking ...
... Inc. (NASDAQ: ONTY ) (TSX: ONY) (the "Company") ... December 31, 2008. , Net income for the year ended ... and $0.36 per diluted share, compared with a net loss ... for the year ended December 31, 2007. The change from ...
... Companies Require Most Dramatic ChangesNEW YORK, March 9 ... rising risk, more than 40 percent of executives surveyed ... say that their companies need to institute significant changes ... according to the results of a new white paper ...
Cached Biology Technology:Spinning carbon nanotubes spawns new wireless applications 2Oncothyreon reports full year and fourth quarter 2008 financial results 2Oncothyreon reports full year and fourth quarter 2008 financial results 3Oncothyreon reports full year and fourth quarter 2008 financial results 4Oncothyreon reports full year and fourth quarter 2008 financial results 5Oncothyreon reports full year and fourth quarter 2008 financial results 6Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 2Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 3Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 4Increasing Economic and Business Risks Will Transform the Global Life Sciences Industry 5
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... 2011 - Genomatix is among the 41 partners of ... as a high impact project within its seventh framework ... data analysis and the development of an intuitive GUI ... within and outside the consortium. "To be part ...
... Bickford from the Department of Biological Sciences at the NUS ... in a recent study, provided compelling evidence from scientific literature ... for many different species all over the world. ... had far-reaching effects on the body size of a wide ...
... discovered that a gene known as an androgen receptor (AR) ... opposite effects on these diseases. In prostate cancer, the AR ... breast cancer, the AR gene promotes cancer growth when the gene ... AR production ceases in women. What this means is that ...
Cached Biology News:Study shows unexpected effect of climate change on body size for many different species 2Researchers discover that same gene has opposite effects in prostate, breast cancers 2
...
Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
... autofluorescent pigment lipofuscin accumulates in the ... neurons. The presence of lipofuscin granules ... microscopy in the central nervous system ... emission spectra, which overlaps with those ...
Biology Products: